Pfizer licenses CD228-targeted ADC to Medicus; RevMed reports fresh lung cancer findings
Pfizer has granted Medicus Pharma co-development rights to PF-08046031, an antibody-drug conjugate targeting CD228 that originated from Seagen. The move shifts responsibility for advancing the asset to Medicus. Separately, RevMed has released updated data from its lung cancer program, and Novartis also made news in the same cycle.
Antibody-drug conjugates remain a focal point in oncology, as they pair tumor-targeting antibodies with potent cytotoxic payloads. Pfizer's decision to license PF-08046031, an asset originally developed by Seagen, to Medicus Pharma reflects a broader industry pattern of shifting early-stage candidates to partners better positioned to advance them. The CD228 target is among several explored for solid tumor applications, though its clinical potential remains under investigation.
The same news cycle also saw RevMed present updated lung cancer data, underscoring the competitive intensity in that indication. With Novartis also active in the space, the period highlights how multiple players are pursuing differentiated mechanisms and biomarkers. For Medicus, taking on co-development rights brings both opportunity and the operational burden of moving a complex biologic forward.
These developments could reshape treatment options for cancer patients if the candidates prove successful, though early-stage data remain uncertain. Licensing deals may accelerate development by distributing risk, but they also concentrate responsibility with smaller firms that may face resource constraints. Lung cancer findings could influence future standards of care, potentially affecting thousands of patients. However, regulatory hurdles and trial outcomes will ultimately determine whether these programs translate into accessible therapies.